Rebirth: Super Banking System Chapter 2328 - 2168: Someone Is Panicking
Previously on Rebirth: Super Banking System...
Suddenly.
A thought struck Shi Ze.
"Let’s go."
"Head to the health department—we have to check it out." He urged right away, convinced that if it truly heals, Huaxia must bring it in, and the faster, the better.
The earlier it happens.
It eases the load on countless families.
If feasible.
Add those medications to the critical illness coverage under medical insurance, letting the nation cover a portion of the expenses to lighten the weight on sufferers. Without doubt, the leaders above will move swiftly on this.
Why such assurance?
Simple cause.
Plenty of funds available.
In particular, with Myanmar, the flow of currency between the nations is massive—you purchase billions in goods from me, I grab billions from you, round and round it goes.
Over many years.
Thus.
When it comes to using Asia Dollars, the top officials remain quite open-handed, as the spent cash gets recouped shortly after. Boosting multiple sectors feels like minting fresh bills.
This cash.
Unlike shelling out precious dollars, the sting feels minimal.
...
Outdoors.
The report raced through nations, sparking massive waves.
United States.
"Oh my God!"
"Is this for real? This firm is incredible—it makes me question if America's vaunted medical setup has lost its way."
"I agree."
"A developing nation outshines our top experts; if it's not about skill, some hidden tale must lurk here."
"Yeah!"
"U.S. drug makers chase profits endlessly—see, here's a firm with real duty; they ought to follow suit."
"Right."
"True, bloodsuckers."
"..."
All at once.
Doubts surged up.
Yet.
They faded quickly.
Folks buzzed with excitement over the fresh remedy from Myanmar Pharmaceutical Group, and over the fact that a fix for this illness now existed. Remember, worldwide, millions upon millions battle Alzheimer’s.
The patient pool swells vast.
Plus.
It heaps heavy strain on families, not just in dollars but deeper in the mind, witnessing dear ones decline bit by bit.
Losing their own identity.
Losing old memories.
This.
Deals the deepest wound. Once the announcement hit, they rushed to the site, placed orders, and in under sixty minutes, slots filled up through three months ahead.
Impossible to avoid.
Sheer volume of demand.
All set in New Yangon City.
...
New Yangon City.
A Western eatery.
Enjoying dinner.
"What?"
After the call came in, Bluem burst out in Chinese, then flipped to "WHAT," mostly from sheer surprise and his ongoing Chinese lessons.
Damn it.
Can't even dine in peace.
"What's up?"
From the opposite seat.
The British envoy inquired with interest; his updates lagged behind Bluem’s, but post-call, Bluem gave a wry grin—the appetite vanished.
"Moments ago."
"Myanmar Pharmaceutical Group revealed their Alzheimer’s therapy cleared clinical trials and launches treatments today."
"..."
Upon hearing it.
The fellow opposite gaped.
For ages.
At last, he muttered, "Bloody hell." He grasped full well what this meant—not mere profits for Myanmar, but... plenty would rage fiercely.
This aspect.
Explains partly why Bluem got the alert so fast; the caller urged him to dig into the particulars, and Bluem did grasp them.
Someone frets.
Frets over what?
Cash flow.
Previous year.
Across the U.S.
Costs for treating Alzheimer’s patients hit what? Close to $200 billion, and that's recurring yearly outlay, not a single hit.
Medications.
Care facilities.
Daily care.
...
The whole linked health network drains from it, or put differently, America's full medical framework bleeds the government dry.
From leaders down.
No exceptions.
Today.
Even at $100,000 a head, healing every U.S. Alzheimer’s case would run about $50 billion.
One-tenth the scale.
God.
The stakes rival those from the prior cancer breakthrough. Note that control meds nearly vanished after Transcription Fluid.
Big U.S. pharma titans despise it bitterly.
Now.
Another fat revenue stream vanishes, beyond anger—they'd love to see forces wipe Myanmar Pharmaceutical Group off the map to feel satisfied.
Sigh!
Bluem let out a breath.
The globe.
Runs on gains in the end; slashing income paths for so many giants and groups means I predict rough times ahead.
...
True enough.
United States.
Leading pharma firms.
"Fuck."
"Xie Te."
"Damn."
"This outfit deserves hell."
"..."
Roars echoed through exec suites at various drug companies; these outfits dreamed everyone globally would buy their pills.
Hence.
Any illness's cure cuts their gains.
Before now.
The initial blow wasn't Patent Liquid, but fruit wine, as folks ditched banned stuff, rendering loads of their treatments useless.
Afterward.
Came Transcription Fluid.
Today.
Yet another key illness category falls; the straight result hits their yearly hauls hard, like a fatal strike for them.
Thus.
Roll out rival meds?
Heh.
They'd love to, but from where?
This differs from high blood pressure, sugar issues, and such—they hold cure methods already, but to keep profits rolling, only idiots would release them.
Unless deranged.
Aren't billions yearly tempting?
Now.
With Alzheimer’s fixed, the mere idea boils their blood—why not stick to Transcription Fluid earnings, why push into new fields recklessly?
"Maybe because we've blocked Transcription Fluid sales in Europe and America for ages, Myanmar Pharmaceutical Group got fed up and struck back hard?"
Right then.
One voice floated this idea.
On that.
All nodded it fit; till now, Euro-American patients jet to Myanmar, yet it doesn't tally—earnings there outpace here.
Why 'strike back'?
Ha!
Insane?
"This isn't the moment to ponder that—we need to hit back, since Myanmar Pharmaceutical Group shatters norms, dooming us to massive hits."
"How?"
"Smear it."
"Build hype."
"Defame."
"Spin stories."
"..."
Suggestions poured out fast; such tactics suit them perfectly—you claim it heals? Heals clean, no side issues?
Heh.
Proof must back it.
And proof.
Lies with media sway, with money's grip, these form core plays; they must leverage clout to nudge the U.S. regime into steps.
Sure.
Tough going.
After all.
If $50 billion settles it, the government spares over $1 trillion in piled-up health budgets over a decade.
So.
Any push for big moves defies logic or heart; whipping up opinion proves hard to rally wide backing, leaving them stumped for now.
This beats targeting tech outfits.
Like Huawei.
Strike there.
It pads Euro-American pockets, officials lose zilch, pushback stays light. But targeting Myanmar Pharmaceutical Group, yes, drug firms profit.
However.
The U.S. regime bleeds trillions.
Caught in middle.
Clashes loom, worlds apart from other strikes.